Surgical procedure and efficacy of KangDuo robot-assisted pyeloplasty for horseshoe kidney.

Authors

Tongchen He, Xiang Wang, Zhihua Li, Pan Song, Qian Yang, Jiyu Yang, Han Bao, Rui Yang, Xicai Zhang, Shubo Fan, Xinfei Li, Kunlin Yang, Hui Jiang, Xuesong Li

Published in

Translational andrology and urology. Volume 15. Issue 9. Pages 336. Sep 30, 2026. Epub Aug 20, 2026.

Abstract

Ureteropelvic junction obstruction (UPJO) in horseshoe kidney (HSK) is surgically challenging because of aberrant anatomy. Robot-assisted pyeloplasty may overcome some limitations of laparoscopy, but data on the Chinese-developed KangDuo (KD) robotic system in HSK are lacking. This study evaluated the surgical procedure and efficacy of KD robot-assisted pyeloplasty for UPJO in HSK.
This retrospective study included 14 adult patients with HSK and UPJO who underwent KD robot-assisted dismembered pyeloplasty between March 2021 and December 2025. Seven procedures used KD-SR1000 and seven used KD-SR2000. Perioperative outcomes, complications, renal function, and follow-up data were analyzed.
All 14 procedures were completed successfully without conversion or intraoperative complications. Preoperatively, 12 patients (85.7%) presented with flank pain, 7 patients (50.0%) had concomitant renal calculi, and 5 patients (35.7%) required preoperative stent insertion. Mean operative time was 200.7 minutes, and median blood loss was 20 mL. One postoperative urinary tract infection (Clavien-Dindo II) occurred. Postoperatively, mean serum creatinine improved from 77.8±17.3 to 69.6±16.6 μmol/L, and mean eGFR improved from 93.8±14.9 to 104.1±13.2 mL/min/1.73 m².All procedures achieved technical success, with no need for reintervention during follow-up.
KD robot-assisted pyeloplasty is safe and feasible for UPJO in HSK and provides satisfactory mid-term outcomes. Larger prospective comparative studies are warranted to confirm these findings and assess cost-effectiveness.

PMID:
42866854
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.